ArticleFrontiers in oncology2023
Prognostic impact of the loss of E-cadherin and
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Association of Epithelial to Mesenchymal transition Markers on Prognosis and Clinicopathological Characteristics in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Head and neck pathology · 2025Pooled it
- Comprehensive Review of the Interplay of MicroRNA and Epithelial-Mesenchymal Transition in Radiation Resistance of Cancer.International journal of molecular sciences · 2026Review
- Clinicopathological Significance of Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- Fusobacterium in the microbiome: from health to disease across the oral-gut axis and beyond.NPJ biofilms and microbiomes · 2025Review
- Article
- Prognostic Value of SOX2 and NANOG Expression in Recurrent Oral Squamous Cell Carcinoma.Cancers · 2025Article
- The diagnostic value of prostate health index combined with soluble e-cadherin for prostate cancer.Frontiers in endocrinology · 2025Article
- Identification of metastasis-associated protein 1 (MTA1) as a new molecular marker for canine urothelial carcinoma.Frontiers in veterinary science · 2025Article
- Review
- Review
- The impact of tumor budding and single-cell invasion on survival in patients with stage III/IV locally advanced oral squamous cell carcinoma- results from a prospective cohort study.Frontiers in oncology · 2024Article
- The interplay of EMT and stemness driving malignant transformation of Oral Submucous Fibrosis.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epithelial-mesenchymal transition (EMT) is a biological mechanism in multiple pathophysiological diseases. Related alterations in cadherin expression play a crucial role in carcinogenesis, progression, angiogenesis, and immune response. EMT cells exhibit a transition from an epithelial to a mesenchymal phenotype (cadherin-switch). This process is characterized by the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.